摘要
近10年来,发现一大批仅用甲胎蛋白(AFP)检测无法确定的肝占位性病变性质的患者。因此当前急需明确我国肝癌患者中AFP阴性占有的比值,以及如何区分肝占位性病变的良恶性类型。本文采用多种肿瘤标志物分别对332例良恶性肝肿瘤患者作血清学诊断以明确肝区良恶性病变对多种肿瘤标志物的表达。同时对各种标志物在临床上应用的价值作进一步的评价。
Multiple tumor markers, including AFP, AFP variants, Gamma-Glutamyl trans-peptidase isoenzyme (iso--GGT)and Alpha-1-antitrypsin(AAT)were used for studying279 cases with liver cancer and 53 with benign liver lesions. The results showed: 1. In82/279 (29.4%) cancer patients and 53/53 cases with benign Iesion, AFP level was20μg/L or less, therefore, not suitable for distinguishing the two patient groups. 2.Tumor markers occurred more frequently in patients with high AFP level. In livercancer patients with an AFP value of 40μg/L or more, the positive rate was 82%forAFP, variants,67% for iso-GGT and 65% for AAT. 3 .The prevalence of multiple tumormarkers in the sera of liver cancer patients was found to be 10%--30% among thosewith an AFP levels below 400μg/L, while it was around 50%--60% in those with highAFP, level. 4.None of tumor markers was appeared in sera of 53 patieats with benignliver lesion.The results indicated that multiple tumor markers could be utilized to dis-tinguish the benign lesion from malignancy in liver;there is a correlation with the AFPlevel and other tumor markers for detection of liver cancer;those early liver cancerpatients with AFP level below 20μg/L need further investigation.
出处
《肿瘤》
CAS
CSCD
北大核心
1991年第2期86-88,共3页
Tumor
